LUPRON DEPOT-6 MONTH 45mg Rx
Generic Name and Formulations:
Leuprolide acetate 45mg; depot susp for IM inj.
Indications for LUPRON DEPOT-6 MONTH 45mg:
Palliative treatment of advanced prostatic carcinoma.
45mg as single IM inj every 6 months (24 weeks). Do not split doses.
Metastatic vertebral lesions. Urinary obstruction. Monitor serum testosterone, PSA, acid phosphatase. Increased risk of diabetes, MI, sudden cardiac death, stroke; monitor blood glucose, HbA1c, and for signs/symptoms of CVD during therapy. History of seizures. Risk of QT prolongation: long-term androgen deprivation therapy, congenital long QT syndrome, electrolyte abnormalities, or CHF. Correct and monitor electrolyte abnormalities; consider monitoring ECGs. Instruct patient on correct self administration. Nursing mothers: not recommended.
Concomitant antiarrhythmics may prolong the QT interval.
Hot flashes/sweats, inj site reaction, initial worsening of signs/symptoms (eg, bone pain, urinary tract obstruction, hematuria), edema, GI disorders, pain, cardiovascular events, CNS and antiandrogenic effects, asthenia, testicular atrophy, urinary disorders, spinal cord compression; hyperglycemia, anaphylactoid, photosensitivity.
Depot kit—1 (prefilled dual-chamber syringe w. supplies)
Sign Up for Free e-newsletters
- 2016 Recommended Immunization Schedule for Adults: What's Changed?
- First Sexually-Transmitted Zika Virus Case Confirmed in Texas
- 2016 Childhood and Adolescent Immunization Schedule Released
- Spiriva Respimat Gains Indication and New Dosage Strength
- To Rx or Not to Rx: Interventions to Improve Antibiotic Prescribing for Uncomplicated Acute RTI
- CDC Guidelines on Preventing Sexual Transmission of Zika Virus Issued
- CDC Updates Interim Zika Virus Guidelines for Pregnant Women and Women of Reproductive Age
- Daklinza Use Expanded to Cover Treatment in More HCV Patients
- Researchers Call for an Alternative Tdap Immunization Strategy for Adolescents
- FDA Announces Large Action Plan in Effort to Reverse the Opioid Epidemic